Literature DB >> 9247577

Complex CD44 splicing combinations in synovial fibroblasts from arthritic joints.

D R Croft1, P Dall, D Davies, D G Jackson, P McIntyre, I M Kramer.   

Abstract

CD44 is a broadly expressed cell surface glycoprotein which is the major cell surface receptor for the glycosaminoglycan, hyaluronan. In humans, alternative splicing of up to 9 variant exons (v2-v10) into CD44 mRNA, together with post-translational modification via glycosylation and chondroitin sulfate attachment has the potential of generating a large number of CD44 isoforms. Insertion of these various exons has the potential to change the functional capacities of the molecule and has implications in disease. We have analyzed CD44 splice variant expression in cultured VCAM-1-positive synovial fibroblasts isolated from patients with osteo- or rheumatoid arthritis and from normal synovium. Rheumatoid and osteoarthritic tissue express CD44 splice variants at the cell surface level. At the mRNA level exons v3, v6, v7, v8, v9 and v10 were detected in different splicing combinations. Rheumatoid tissue showed high expression, osteoarthritic tissues showed great variation. In contrast, non-inflamed tissue showed no splicing events. Our results indicate that the nature of CD44 splice variant expression may be linked to the inflammatory state of the synovial joint.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247577     DOI: 10.1002/eji.1830270713

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Trojan horses and guided missiles: targeted therapies in the war on arthritis.

Authors:  Mathieu Ferrari; Shimobi C Onuoha; Costantino Pitzalis
Journal:  Nat Rev Rheumatol       Date:  2015-03-03       Impact factor: 20.543

2.  The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  A Wibulswas; D Croft; I Bacarese-Hamilton; P McIntyre; E Genot; I M Kramer
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 3.  Alternative splicing in multiple sclerosis and other autoimmune diseases.

Authors:  Irina Evsyukova; Jason A Somarelli; Simon G Gregory; Mariano A Garcia-Blanco
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

4.  Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-06-01

5.  Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.

Authors:  Stefan Bauer; Michael C Jendro; Andreas Wadle; Sascha Kleber; Frank Stenner; Robert Dinser; Anja Reich; Erica Faccin; Stefan Gödde; Harald Dinges; Ulf Müller-Ladner; Christoph Renner
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

6.  Adipokines and Inflammation Alter the Interaction Between Rheumatoid Arthritis Synovial Fibroblasts and Endothelial Cells.

Authors:  Rebecca Hasseli; Klaus W Frommer; Maria Schwarz; Marie-Lisa Hülser; Carina Schreiyäck; Mona Arnold; Magnus Diller; Ingo H Tarner; Uwe Lange; Joern Pons-Kühnemann; Markus Schönburg; Stefan Rehart; Ulf Müller-Ladner; Elena Neumann
Journal:  Front Immunol       Date:  2020-06-02       Impact factor: 7.561

Review 7.  CD44 in rheumatoid arthritis.

Authors:  David Naor; Shlomo Nedvetzki
Journal:  Arthritis Res Ther       Date:  2003-02-28       Impact factor: 5.156

8.  Altered expression of protein tyrosine phosphatase, non-receptor type 22 isoforms in systemic lupus erythematosus.

Authors:  Hui-Hsin Chang; William Tseng; Jing Cui; Karen Costenbader; I-Cheng Ho
Journal:  Arthritis Res Ther       Date:  2014-01-17       Impact factor: 5.156

9.  Biomimetic collagenous scaffold to tune inflammation by targeting macrophages.

Authors:  Francesca Taraballi; Bruna Corradetti; Silvia Minardi; Sebastian Powel; Fernando Cabrera; Jeff L Van Eps; Bradley K Weiner; Ennio Tasciotti
Journal:  J Tissue Eng       Date:  2016-02-01       Impact factor: 7.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.